Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE) and Ironwood Pharma (IRWD)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Neurogene (NGNE – Research Report) and Ironwood Pharma (IRWD – Research Report).
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Neurogene (NGNE)
In a report released today, Ryan Sigdahl from Craig-Hallum maintained a Buy rating on Neurogene. The company’s shares closed last Thursday at $26.69.
According to TipRanks.com, Sigdahl is a 4-star analyst with an average return of
Currently, the analyst consensus on Neurogene is a Strong Buy with an average price target of $60.33, representing an 117.5% upside. In a report issued on October 22, H.C. Wainwright also reiterated a Buy rating on the stock with a $45.00 price target.
See today’s best-performing stocks on TipRanks >>
Ironwood Pharma (IRWD)
Craig-Hallum analyst Chase Knickerbocker maintained a Hold rating on Ironwood Pharma today. The company’s shares closed last Thursday at $1.96, close to its 52-week low of $1.34.
According to TipRanks.com, Knickerbocker is a top 100 analyst with an average return of
The word on The Street in general, suggests a Hold analyst consensus rating for Ironwood Pharma with a $1.00 average price target, representing a -51.2% downside. In a report issued on October 22, TR | OpenAI – 4o also reiterated a Hold rating on the stock with a $1.50 price target.
Read More on NGNE:
Disclaimer & DisclosureReport an Issue
- Neurogene doses first patient in NGN-401 clinical trial
- Neurogene Begins Dosing in Rett Syndrome Trial
- Neurogene price target raised to $65 from $45 at H.C. Wainwright
- Neurogene Inc.’s NGN-401: A Promising Gene Therapy for Rett Syndrome
- Neurogene’s Strategic Advances and Expanded Embolden Trial Drive Buy Rating
